Dr. Alexander Fleming, founder of Kinexum, a strategic advisory firm that provides regulatory and clinical development guidance for life science product development, observed many barriers to translating breakthroughs into public health protocols, including: (i) lack of a clear regulatory pathway for approval of therapeutic interventions; (ii) the need for clinical trials that are too large and last too long to attract funding to demonstrate prevention or delay of chronic diseases; and (iii) misalignment of incentives for a payer to reimburse an intervention today that might only benefit another reimburse years later.
Dr. Fleming re-imagined the regulatory system and our national health focus around aging to increase the speed (with safety) of scientific advances and make geroscience an integral part of public health. He believed that a not-for-profit organization could play a leading role in catalyzing stakeholders to take the moonshot to increased healthspan for all.
Therefore, in the spring of 2020, Kinexum decided to form the not-for-profit, The Kitalys Institute, to organize the Metabesity conferences and related events, Project Healthspan, and other initiatives to translate emerging science into the material, accessible gains in public health.
Learn about how we got here today
Innovative thinking fueled by experience
The Kitalys Institute's original organizer is Kinexum, a strategic advisory firm that provides regulatory and clinical development guidance for life science product development. Kinexum's founder and Executive Chairman is G. Alexander ("Zan") Fleming, M.D. Dr. Fleming is an endocrinologist who led the medical reviews at the U.S. FDA that resulted in approval, among others, of metformin and the first statin, insulin analogue, PPAR agonist, and growth hormone for non-growth hormone deficiency conditions.
During his tenure at the FDA, Dr. Fleming had an epiphany that emerging geroscience held out the prospect of preventing or delaying chronic diseases by delaying or even reversing biological aging. He recognized the efficacy of moving from a focus on individual diseases to one that considers all the common causes of aging. The frailty, chronic illness, and morbidity that aging itself usually brings could be prevented if such a shift were made.